drugset / Trial / NCT07553442

A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran

NCT07553442

Phase 2 Recruiting 93 enrolled Alnylam Pharmaceuticals Hoffmann-La Roche · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy, pharmacodynamics (PD), and safety of ALN-AGT01 RVR in participants with mild to moderate hypertension pretreated with zilebesiran.

Timeline

Start
2026-04-27
Primary completion
2028-04-01
Completion
2028-10-01

Drugs

EvaluationDrugModalityDoseRoute
Subject ALN-AGT01 RVR Unknown Subcutaneous
Background Zilebesiran Unknown Subcutaneous

Indications